• Principal Investigator
  • Male

Prof. dr. J. Booij

Position: Professor
Main activities: Patient care, Research
Specialisation: neuroreceptor imaging
foto J. Booij is one of the AMC Principal Investigators
Focus of research:

Our research is focussed on neuroreceptor imaging with SPECT and PET, with special interests in Parkinson's disease, dementia with Lewy bodies, schizophrenia, addiction, major depression, and neurotoxicity of XTC. In addiction, preclinial research is focussed on the development of new SPECT and PET tracers, and SPECT imaging in small laboratory animals

AMC themes: Neurological & Psychiatric Disorders
Departments: Nuclear Medicine
Bähler L. Keep cool and stay lean. S.l.: s.n.; 2017. 214p. ISBN 978-94-6233-535-6 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Booij J, Hoekstra JBL; copromotor(s): Holleman F, Verberne HJ)
Bahler L, Holleman F, Booij J, Hoekstra JB, Verberne HJ, Hot heads & cool bodies: The conundrums of human brown adipose tissue (BAT) activity research. EUR J INTERN MED 2017;40:26-29 [PubMed]
Bahler L, Holleman F, Chan MW, Booij J, Hoekstra JB, Verberne HJ, 18F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure. PLOS ONE 2017;12 (5):e0176242 [PubMed]
Bahler L, Verberne HJ, Soeters MR, Booij J, Hoekstra JB, Holleman F, Dopaminergic Effects on Brown Adipose Tissue (DEBAT): A prospective physiological study. DIABETES METAB 2017;43 (2):172-175 [PubMed]
Bakker G. Innovative Approaches to Understanding the Neurobiology of Psychosis. S.l.: s.n.; 2017. 137p. Proefschrift University Maastricht, Department of Psychiatry & Psychology. (Promotor(s): Booij J, van Amelsvoort TAMJ; copromotor(s): Caan MWA, Bloemen OJN)
Booij J, Dubroff J, Pryma D, Yu J, Agarwal R, Lakhani P, Kuo PH, Diagnostic Performance of the Visual Reading of (123)I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia. J NUCL MED 2017;58 (11):1821-1826 [PubMed]
Boot E, Hollak CEM, Huijbregts SCJ, Jahja R, van Vliet D, Nederveen AJ, Nieman DH, Bosch AM, Bour LJ, Bakermans AJ, Abeling NGGM, Bassett AS, van Amelsvoort TAMJ, van Spronsen FJ, Booij J, Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria. PSYCHOL MED 2017;ahead of print [PubMed]
Dickson JC, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S, Assenbaum-Nan S, Borght TV, Pagani M, Kapucu OL, Hesse S, van Laere K, Darcourt J, Varrone A, Tatsch K, The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [(123)I]FP-CIT SPECT imaging. EJNMMI RES 2017;7 (1):10 [PubMed]
Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH, Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. ACTA NEUROPATHOL 2017;133 (4):535-545 [PubMed]
Joling M, van den Heuvel OA, Berendse HW, Booij J, Vriend C, Serotonin transporter binding and anxiety symptoms in Parkinson's disease. J NEUROL NEUROSUR PS 2017;ahead of print [PubMed]
Joling M, Vriend C, van den Heuvel OA, Raijmakers PGHM, Jones PA, Berendse HW, Booij J, Analysis of Extrastriatal (123)I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. J NUCL MED 2017;58 (7):1117-1123 [PubMed]
Kasanova Z, Ceccarini J, Frank MJ, van Amelsvoort T, Booij J, Heinzel A, Mottaghy F, Myin-Germeys I, Striatal dopaminergic modulation of reinforcement learning predicts reward-oriented behavior in daily life. BIOL PSYCHOL 2017;127:1-9 [PubMed]
Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, Reetz K, Overeem S, Pijpers A, Reesink FE, van Laar T, Heinen L, Teune LK, Höffken H, Luster M, Kesper K, Adriaanse SM, Booij J, Leenders KL, Oertel WH, FDG PET, Dopamine Transporter SPECT, and Olfaction: Combining Biomarkers in REM Sleep Behavior Disorder. MOVEMENT DISORD 2017;32 (10):1482-1486 [PubMed]
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, van de Giessen E, Villemagne V, Barthel H, The need of standardization and of large clinical studies in an emerging indication of [18 F] FDG PET: the autoimmune encephalitis (vol 44, pg 353, 2017). EUR J NUCL MED MOL I 2017;44 (3):559-560 [PubMed]
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Saraf LJ, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, van de Giessen E, Villemagne V, Barthel H, The need of standardization and of large clinical studies in an emerging indication of [F-18]FDG PET: the autoimmune encephalitis. EUR J NUCL MED MOL I 2017;44 (3):353-357 [PubMed]
Schrantee A, Tremoleda JL, Wylezinska-Arridge M, Bouet V, Hesseling P, Meerhoff GF, de Bruin KM, Koeleman J, Freret T, Boulouard M, Desfosses E, Galineau L, Gozzi A, Dauphin F, Gsell W, Booij J, Lucassen PJ, Reneman L, Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate. PLOS ONE 2017;12 (2):e0172776 [PubMed]
Schrantee A, Václavů L, Reneman L, Verberne HJ, Booij J, Tan HL, QT prolongation by dexamphetamine: Does experience matter?. J CARDIOVASC ELECTR 2017;28 (8):912-916 [PubMed]
Selten JP, Booij J, Buwalda B, Meyer-Lindenberg A, Biological Mechanisms Whereby Social Exclusion May Contribute to the Etiology of Psychosis: A Narrative Review. SCHIZOPHRENIA BULL 2017;43 (2):287-292 [PubMed]
Shalgunov V. Development of 18F-labeled agonist radioligands for the imaging of the high-affinity state of dopamine D2/3 receptors in the central nervous system by positron emission tomography (PET). S.l.: s.n.; 2017. 282p. Proefschrift University of Groningen, Department of Nuclear Medicine and Molecular Imaging. (Promotor(s): Elsinga PH, Booij J; copromotor(s): Dierckx RAJO)
Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, Borght TV, Jonsson C, de Nijs R, Hesse S, Koulibaly PM, Akdemir UO, Koole M, Tatsch K, Varrone A, [(123)I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI PHYS 2017;4 (1):8 [PubMed]
van Galen KA, ter Horst KW, Booij J, la Fleur SE, Serlie MJ, The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies. METABOLISM 2017;ahead of print [PubMed]
Versteeg RI, Koopman KE, Booij J, Ackermans MT, Unmehopa UA, Fliers E, la Fleur SE, Serlie MJ, Serotonin Transporter Binding in the Diencephalon Is Reduced in Insulin-Resistant Obese Humans. NEUROENDOCRINOLOGY 2017;105 (2):141-149 [PubMed]
Versteeg RI, Schrantee A, Adriaanse SM, Unmehopa UA, Booij J, Reneman L, Fliers E, la Fleur SE, Serlie MJ, Timing of caloric intake during weight loss differentially affects striatal dopamine transporter and thalamic serotonin transporter binding. FASEB J 2017;31 (10):4545-4554 [PubMed]
Vingerhoets C, Bakker G, van Dijk J, Bloemen OJN, Wang Y, Chan RCK, Booij J, van Amelsvoort TAMJ, The effect of the muscarinic M-1 receptor antagonist biperiden on cognition in medication free subjects with psychosis. EUR NEUROPSYCHOPHARM 2017;27 (9):854-864 [PubMed]
Vingerhoets WAM. Investigating neurobiological mechanisms underlying comorbid cognitive symptoms in psychosis and substance use. S.l.: s.n.; 2017. 221p. ISBN 978-94-6299-552-9 Proefschrift Maastricht University, Faculty of Health, Medicine and Life Sciences. (Promotor(s): Booij J, Bloemen OJN; copromotor(s): Oswald JN)
Zoons E, Booij J, Speelman JD, Dreissen YEM, Smit M, Tijssen MAJ, Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms. EJNMMI RES 2017;7 (1):87 [PubMed]
Zoons E, Tijssen MAJ, Dreissen YEM, Speelman JD, Smit M, Booij J, The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. EUR J NUCL MED MOL I 2017;44 (8):1375-1382 [PubMed]
Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu LÖA, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Sabri O, Hesse S, Borght TV, van Laere K, Tatsch K, la Fougère C, Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. EUR J NUCL MED MOL I 2016;43 (7):1315-1322 [PubMed]
Bahler L, Holleman F, Booij J, Hoekstra JB, Verberne HJ, Interobserver and intraobserver variability for the assessment of brown adipose tissue activity on 18F-FDG PET-CT. NUCL MED COMMUN 2016;37 (4):363-371 [PubMed]
Bahler L, Verberne HJ, Brakema E, Tepaske R, Booij J, Hoekstra JB, Holleman F, Bromocriptine and insulin sensitivity in lean and obese subjects. ENDOCR CONNECT 2016;5 (6):44-52 [PubMed]
Bakker G, Caan MWA, Schluter RS, Bloemen OJN, da Silva-Alves F, de Koning MB, Boot E, Vingerhoets WAM, Nieman DH, de Haan L, Booij J, van Amelsvoort TAMJ, Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis. PSYCHOL MED 2016;46 (11):2299-2311 [PubMed]
Bakker G, Caan MWA, Vingerhoets WAM, da Silva-Alves F, de Koning M, Boot E, Nieman DH, de Haan L, Bloemen OJ, Booij J, van Amelsvoort TAMJ, Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. PLOS ONE 2016;11 (11):e0159928 [PubMed]
Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, Asenbaum S, Booij J, Atay Kapucu LÖ, Svarer C, Koulibaly PM, Nobili F, Pagani M, Sabri O, Sera T, Tatsch K, Vander Borght T, van Laere K, Varrone A, Iida H, Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. EUR J NUCL MED MOL I 2016;43 (7):1323-1336 [PubMed]
Gevonden M, Myin-Germeys I, Wichers M, Booij J, van den Brink W, van Winkel R, Selten JP, Reactivity to social stress in ethnic minority men. PSYCHIAT RES 2016;246:629-636 [PubMed]
Heijtel DFR, Petersen ET, Mutsaerts HJMM, Bakker E, Schober P, Stevens MF, van Berckel BNM, Majoie CBLM, Booij J, van Osch MJP, van Bavel ET, Boellaard R, Lammertsma AA, Nederveen AJ, Quantitative agreement between [(15)O]H2O PET and model free QUASAR MRI-derived cerebral blood flow and arterial blood volume. NMR BIOMED 2016;29 (4):519-526 [PubMed]
Koopman KE, Roefs A, Elbers DCE, Fliers E, Booij J, Serlie MJ, La Fleur SE, Brain dopamine and serotonin transporter binding are associated with visual attention bias for food in lean men. PSYCHOL MED 2016;46 (8):1707-1717 [PubMed]
Schrantee A, Ferguson B, Stoffers D, Booij J, Rombouts S, Reneman L, Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls. BRAIN IMAGING BEHAV 2016;10 (2):548-558 [PubMed]
Siepel FJ, Dalen I, Grüner R, Booij J, Brønnick KS, Buter TC, Aarsland D, Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. MOVEMENT DISORD 2016;31 (1):118-125 [PubMed]
van der Zande JJ, Booij J, Scheltens P, Raijmakers PGHM, Lemstra AW, [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. EUR J NUCL MED MOL I 2016;43 (6):1060-1066 [PubMed]
van der Zwaal EM, de Weijer BA, van de Giessen EM, Janssen I, Berends FJ, van de Laar A, Ackermans MT, Fliers E, la Fleur SE, Booij J, Serlie MJ, Striatal dopamine D-2/3 receptor availability increases after long-term bariatric surgery-induced weight loss. EUR NEUROPSYCHOPHARM 2016;26 (7):1190-1200 [PubMed]
Vegting Y, Reneman L, Booij J, The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. PSYCHOPHARMACOLOGY 2016;233 (19-20):3473-3501 [PubMed]
Verschure DO, Boot E, van Amelsvoort TA, Booij J, van Eck-Smit BLF, Somsen GA, Verberne HJ, Cardiac sympathetic activity in 22q11.2 deletion syndrome. INT J CARDIOL 2016;212:346-351 [PubMed]
Verschure DO, Boot E, van Amelsvoort TA, Booij J, van Eck-Smit BLF, Somsen GA, Verberne HJ, Corrigendum to "Cardiac sympathetic activity in 22q11.2 deletion syndrome" [Int. J. Cardiol. 212 (2016) 346-351]. INT J CARDIOL 2016;222:1141 [PubMed]
Vulink NC, Planting RS, Figee M, Booij J, Denys D, Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder. EUR NEUROPSYCHOPHARM 2016;26 (2):350-356 [PubMed]
Zaaijer E R, Goudriaan AE, Koeter MWJ, Booij J, Wim van den Brink (red.) W, Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. SUBST USE MISUSE 2016;51 (14):1905-1911 [PubMed]
Bakker G, Vingerhoets WA, van Wieringen JP, de Bruin K, Eersels J, de Jong J, Chahid Y, Rutten BP, Dubois S, Watson M, Mogg AJ, Xiao H, Crabtree M, Collier DA, Felder CC, Barth VN, Broad LM, Bloemen OJ, van Amelsvoort TA, Booij J, I-123-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M-1 In Vivo. J NUCL MED 2015;56 (2):317-322 [PubMed]
Bongers P, van de Giessen E, Roefs A, Nederkoorn C, Booij J, van den Brink W, Jansen A, Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods. HEALTH PSYCHOL 2015;34 (6):677-685 [PubMed]
de Kwaasteniet BP, Pinto C, Ruhé HG , van Wingen GA, Booij J, Denys D, Striatal Dopamine D-2/3 Receptor Availability in Treatment Resistant Depression (vol 9, e113612, 2014). PLOS ONE 2015;10 (8):e0135764 [PubMed]
Gevonden MJ. The odd one out : exploring the nature of the association between minority status and psychosis. S.l.: s.n.; 2015. 111p. ISBN 9789090292045 Proefschrift Maastricht University, MHeNs School for Mental Health and Neuroscience. (Promotor(s): Selten JP, Booij J; copromotor(s): Germeys I)
Gevonden MJ, Myin-Germeys I, van den Brink W, van Os J, Selten JP, Booij J, Psychotic reactions to daily life stress and dopamine function in people with severe hearing impairment. PSYCHOL MED 2015;45 (8):1665-1674 [PubMed]
Hernaus D, Collip D, Kasanova Z, Winz O, Heinzel A, van Amelsvoort T, Shali SM, Booij J, Rong Y, Piel M, Pruessner J, Mottaghy FM, Myin-Germeys I, No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder. TRANSL PSYCHIAT 2015;5:e547 [PubMed]
Schrantee A, Václavů L, Heijtel DFR, Caan MWA, Gsell W, Lucassen PJ, Nederveen AJ, Booij J, Reneman L, Dopaminergic system dysfunction in recreational dexamphetamine users. NEUROPSYCHOPHARMACOL 2015;40 (5):1172-1180 [PubMed]
Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RAJO, Michel MC, Booij J, Elsinga PH, Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D 2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers. EJNMMI RES 2015;5 (1):119 [PubMed]
Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RAJO, Michel MC, Booij J, Elsinga PH, Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET. J NUCL MED 2015;56 (1):133-139 [PubMed]
Suwijn SR, van Boheemen CJM, de Haan RJ, Tissingh G, Booij J, de Bie RMA, The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. EJNMMI RES 2015;5:12 [PubMed]
van Wieringen JP. Evaluation of potential agonist radioligands for imaging dopamine D2/3 receptors. S.l.: s.n.; 2015. 249p. ISBN 9789461696175 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Booij J, Michel MC; copromotor(s): Elsinga PH)
Zaaijer ER. Chasing the dragon away: Personality as a protective factor and extended-release naltrexone as a treatment for heroin dependence. S.l.: s.n.; 2015. 117p. ISBN 978-94-6182-577-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Booij J, van den Brink W; copromotor(s): Goudriaan AE)
Zaaijer ER, de Bruin K, la Fleur SE, Goudriaan AE, van den Brink W, Booij J, Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. J PSYCHOPHARMACOL 2015;29 (3):344-348 [PubMed]
Zaaijer ER, van Dijk L, de Bruin K, Goudriaan AE, Lammers LA, Koeter MWJ, van den Brink W, Booij J, Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. PSYCHOPHARMACOLOGY 2015;232 (14):2597-2607 [PubMed]
Bernsen MR, Vaissier PEB, van Holen R, Booij J, Beekman FJ, de Jong M, The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI. EUR J NUCL MED MOL I 2014;41 (1):S36-S49 [PubMed]
Booij J, Tijssen MAJ, Berendse HW. Clinical Applications of [123I]FP-CIT SPECT Imaging in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. Berlin; Heidelberg: Springer; 2014., p. 719-736
Booij J, van Loon G, de Bruin K, Voorn P, Acute administration of haloperidol does not influence 123I-FP-CIT binding to the dopamine transporter. J NUCL MED 2014;55 (4):647-649 [PubMed]
Crunelle CL, van den Brink W, Dom G, Booij J, Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. BRIT J PSYCHIAT 2014;204 (6):486-487 [PubMed]
de Koning MB, Bloemen OJN, van Duin EDA, Booij J, Abel KM, de Haan L, Linszen DH, van Amelsvoort TAMJ, Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. J PSYCHOPHARMACOL 2014;28 (6):553-560 [PubMed]
de Kwaasteniet BP, Pinto C, Ruhé HG , Ruhé EHG, van Wingen GA, Booij J, Denys D, Striatal dopamine D2/3 receptor availability in treatment resistant depression. PLOS ONE 2014;9 (11):e113612 [PubMed]
de Weijer BA, van de Giessen E, Janssen I, Berends FJ, van de Laar A, Ackermans MT, Fliers E, la Fleur SE, Booij J, Serlie MJ, Striatal dopamine receptor binding in morbidly obese women before and after gastric bypass surgery and its relationship with insulin sensitivity. DIABETOLOGIA 2014;57 (5):1078-1080 [PubMed]
Figee M, de Koning P, Klaassen S, Vulink N, Mantione M, van den Munckhof P, Schuurman R , van Wingen G, van Amelsvoort T, Booij J, Denys D, Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. BIOL PSYCHIAT 2014;75 (8):647-652 [PubMed]
Gevonden M, Booij J, van den Brink W, Heijtel D, van Os J, Selten JP, Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia. JAMA PSYCHIAT 2014;71 (12):1364-1372 [PubMed]
Heijtel DFR, Mutsaerts HJMM, Bakker E, Schober P, Stevens MF, Petersen ET, van Berckel BNM, Majoie CBLM, Booij J, van Osch MJP, VanBavel E, Boellaard R, Lammertsma AA, Nederveen AJ, Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: a head-to-head comparison with ¹⁵O H₂O positron emission tomography. NEUROIMAGE 2014;92:182-192 [PubMed]
Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Darcourt J, Akdemir UO, Knudsen GM, Nobili F, Pagani M, Vander Borght T, van Laere K, Varrone A, Tatsch K, Sabri O, Booij J, Association of central serotonin transporter availability and body mass index in healthy Europeans. EUR NEUROPSYCHOPHARM 2014;24 (8):1240-1247 [PubMed]
Knol RJJ, de Bruin K, Opmeer B, Voorn P, Jonker AJ, van Eck-Smit BLF, Booij J, Decreased ipsilateral [¹²³I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats. NUCL MED BIOL 2014;41 (1):90-95 [PubMed]
Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu OL, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Hesse S, Vander Borght T, van Laere K, Tatsch K, la Fougère C, Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. EUR J NUCL MED MOL I 2014;41 (10):1938-1946 [PubMed]
Koopman KEM. Central serotonin and dopamine transporters in overeating, obesity and insulin resistance. Amsterdam: s.n.; 2014. 176p. ISBN 978-90-9028511-5 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Fliers E, Booij J; copromotor(s): La Fleur SE, Serlie MJM)
Ossenkoppele R, Booij J, Scheltens P, van Berckel BNM. Dementia due to neurodegenerative disease: Molecular imaging findings in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. Berlin; Heidelberg: Springer; 2014., p. 185-211
Ruhé HG , Koster M, Booij J, van Herk M, Veltman DJ, Schene AH, Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. PSYCHIAT RES 2014;221 (2):155-161 [PubMed]
Ruhé HG , Visser AKD, Frokjaer VG, Haarman BCM, Klein HC, Booij J. Molecular imaging of depressive disorders in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, den Boer JA, editors. PET and SPECT in psychiatry. Berlin; Heidelberg: Springer; 2014., p. 93-172
Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O'Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID, Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J NUCL MED 2014;55 (8):1288-1296 [PubMed]
Sharifi S, Nederveen AJ, Booij J, van Rootselaar AF, Neuroimaging essentials in essential tremor: A systematic review. NEUROIMAGE-CLIN 2014;5:217-231 [PubMed]
Siepel FJ, Brønnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, Grüner R, Aarsland D, Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. MOVEMENT DISORD 2014;29 (14):1802-1808 [PubMed]
Suwijn SR , Berendse HW, Verschuur CVM, de Bie RMA, Booij J, Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy. ISRN NEUROL 2014;2014:345132 [PubMed]
Suwijn SR, de Bruin K, de Bie RMA, Booij J, The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease. PARKINSONISM RELAT D 2014;20 (Suppl. 1):S184-S186 [PubMed]
van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J, Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. J PSYCHOPHARMACOL 2014;28 (9):866-873 [PubMed]
van de Giessen E, McIlwrick S, Veltman D, van den Brink W, Booij J. Obesity an addiction? Imaging of neurotransmitter systems in obesity in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, den Boer JA, editors. PET and SPECT in psychiatry. Berlin; Heidelberg: Springer; 2014., p. 641-656
van Wieringen JP, de Bruin K, Janssen HM, Fransen PM, Janssen AGM, van Doremalen PA, Michel MC, Elsinga PH, Booij J, Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors. INT J MOL IMAGING 2014;2014:507012 [PubMed]
van Wieringen JP, Michel MC, Janssen HM, Janssen AG, Elsinga PH, Booij J, Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. EJNMMI RES 2014;4:53 [PubMed]
van Wieringen JP, Shalgunov V, Janssen HM, Fransen PM, Janssen AGM, Michel MC, Booij J, Elsinga PH, Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state. J MED CHEM 2014;57 (2):391-410 [PubMed]
Verschure DO, Somsen GA, van Eck-Smit BLF, Knol RJJ, Booij J, Verberne HJ, Tako-tsubo cardiomyopathy: how to understand possible pathophysiological mechanism and the role of (123)I-MIBG imaging. J NUCL CARDIOL 2014;21 (4):730-738 [PubMed]
Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, Voorn P, Raijmakers P, Foncke EMJ, van de Giessen E, Berendse HW, van den Heuvel OA, Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. MOVEMENT DISORD 2014;29 (7):904-911 [PubMed]
Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S, Berendse HW, van den Heuvel OA, Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?. NEUROSCI BIOBEHAV R 2014;38:60-71 [PubMed]
Zaaijer ER, Bruijel J, Blanken P, Hendriks V, Koeter MWJ, Kreek MJ, Booij J, Goudriaan AE, van Ree JM, van den Brink W, Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. DRUG ALCOHOL DEPEN 2014;145:101-105 [PubMed]
Zoons E, Booij J, de Jong B, Tijssen MAJ. PET and SPECT imaging in dystonia in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. Berlin; Heidelberg: Springer; 2014., p. 667-689
Zoons E, Sharifi S, Booij J, de Jong B, Tijssen MAJ. PET and SPECT imaging in hyperkinetic movement disorders in: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. Berlin; Heidelberg: Springer; 2014., p. 691-717
Bloemen OJN, de Koning MB, Gleich T, Meijer J, de Haan L, Linszen DH, Booij J, van Amelsvoort TAMJ, Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. EUR NEUROPSYCHOPHARM 2013;23 (2):126-132 [PubMed]
Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, Pappatà S, Tatsch K, Walker Z, Pagani M, Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. EUR J NUCL MED MOL I 2013;40 (7):1122-1125 [PubMed]
Booij J, Reneman L, Alders M, Kuijpers TW, Increase in central striatal dopamine transporters in patients with Shwachman-Diamond syndrome: additional evidence of a brain phenotype. AM J MED GENET A 2013;161A (1):102-107 [PubMed]
Booij J, van de Giessen E, Hesse S, Sabri O, Comments on Eusebio et al.: Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. EUR J NUCL MED MOL I 2013;40 (1):143-144 [PubMed]
Borgers AJ, Alkemade A, van de Giessen EM, Drent ML, Booij J, Bisschop PH, Fliers E, Imaging of serotonin transporters with [I-123]FP-CIT SPECT in the human hypothalamus. EJNMMI RES 2013;3 (1):UNSP 34 [PubMed]
Crunelle CL, van de Giessen E, Schulz S, Vanderschuren LJMJ, de Bruin K, van den Brink W, Booij J, Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. ADDICT BIOL 2013;18 (6):908-911 [PubMed]
Crunelle CL, van den Brink W, Veltman DJ, van Emmerik-van Oortmerssen K, Dom G, Schoevers RA, Booij J, Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. EUR NEUROPSYCHOPHARM 2013;23 (12):1714-1723 [PubMed]
Crunelle CL, Veltman DJ, van Emmerik-van Oortmerssen K, Booij J, van den Brink W, Impulsivity in adult ADHD patients with and without cocaine dependence. DRUG ALCOHOL DEPEN 2013;129 (1-2):18-24 [PubMed]
de Koning M. Studying biomarkers in populations at genetic and clinical high risk for psychosis. s.l.: s.n.; 2013. 200p. Proefschrift Maastricht University, Medicine. (Promotor(s): van Amelsvoort TAMJ, Booij J; copromotor(s): )
Goorden MC, van der Have F, Kreuger R, Ramakers RM, Vastenhouw B, Burbach JPH, Booij J, Molthoff CFM, Beekman FJ, VECTor: a preclinical imaging system for simultaneous submillimeter SPECT and PET. J NUCL MED 2013;54 (2):306-312 [PubMed]
Koopman KE, Booij J, Fliers E, Serlie MJ, la Fleur SE, Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region. MOL METAB 2013;2 (4):417-422 [PubMed]
Nobili F, Naseri M, de Carli F, Asenbaum S, Booij J, Darcourt J, Ell P, Kapucu O, Kemp P, Svarer C, Morbelli S, Pagani M, Sabri O, Tatsch K, Tossici-Bolt L, Sera T, Borght TV, van Laere K, Varrone A, Erratum to: Automatic semi-quantification of [(123)I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. EUR J NUCL MED MOL I 2013;40 (4):640-641
Nobili F, Naseri M, de Carli F, Asenbaum S, Booij J, Darcourt J, Ell P, Kapucu O, Kemp P, Svarer C, Varer C, Morbelli S, Pagani M, Sabri O, Tatsch K, Tossici-Bolt L, Sera T, Vander Borght T, van Laere K, Varrone A, Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. EUR J NUCL MED MOL I 2013;40 (4):565-573 [PubMed]
Schouw MLJ, Caan MWA, Geurts HM, Schmand B, Booij J, Nederveen AJ, Reneman L, Monoaminergic dysfunction in recreational users of dexamphetamine. EUR NEUROPSYCHOPHARM 2013;23 (11):1491-1502 [PubMed]
Schouw MLJ, Kaag AM, Caan MWA, Heijtel DFR, Majoie CBLM, Nederveen AJ, Booij J, Reneman L, Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI. NEUROIMAGE 2013;72:1-9 [PubMed]
Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, Aarsland D, (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ OPEN 2013;3 (4):e002642 [PubMed]
Söderlund TA, Dickson JC, Prvulovich E, Ben-Haim S, Kemp P, Booij J, Nobili F, Thomsen G, Sabri O, Koulibaly PM, Akdemir OU, Pagani M, van Laere K, Asenbaum-Nan S, George J, Sera T, Tatsch K, Bomanji J, Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies. J NUCL MED 2013;54 (5):714-722 [PubMed]
Suwijn SR, Berendse HW, Verschuur CVM, Winogrodzka A, de Bie RMA, Booij J, SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias. EJNMMI RES 2013;3 (1):UNSP 44 [PubMed]
Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S, Booij J, Darcourt J, Dickson JC, Kapucu OL, Nobili F, Sabri O, Sera T, Tatsch K, Tossici-Bolt L, van Laere K, Borght TV, Varrone A, Pagani M, Pinborg LH, No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [I-123]FP-CIT (DaTSCAN) and SPECT. EJNMMI RES 2013;3 (1):UNSP 39 [PubMed]
van de Giessen E, Hesse S, Caan MWA, Zientek F, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Guignard R, Akdemir UO, Knudsen GM, Nobili F, Pagani M, Vander Borght T, van Laere K, Varrone A, Tatsch K, Booij J, Sabri O, No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. NEUROIMAGE 2013;64:61-67 [PubMed]
van de Giessen E, La Fleur SE, Eggels L, de Bruin K, van den Brink W, Booij J, High fat/carbohydrate ratio but not total energy intake induces lower striatal dopamine D2/3 receptor availability in diet-induced obesity. INT J OBESITY 2013;37 (5):754-757 [PubMed]
van Wieringen JP, Booij J, Shalgunov V, Elsinga P, Michel MC, Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. N-S ARCH PHARMACOL 2013;386 (2):135-154 [PubMed]
van Wingen GA, van den Brink W, Veltman DJ, Schmaal L, Dom G, Booij J, Crunelle CL, Reduced striatal brain volumes in non-medicated adult ADHD patients with comorbid cocaine dependence. DRUG ALCOHOL DEPEN 2013;131 (3):198-203 [PubMed]
Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu OL, Kluge A, Knudsen GM, Koulibaly PM, Nobili F, Pagani M, Sabri O, Vander Borght T, van Laere K, Tatsch K, European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. EUR J NUCL MED MOL I 2013;40 (2):213-227 [PubMed]
Al Hussainy R. Iodine-123 and flurine-18 radiolabeled analogues of WAY-100635 as potential radioligands for imaging the 5-HT1A receptor in the brain. s.l.: s.n.; 2012. 150p. Proefschrift Vrije Universiteit Amsterdam, faculteit Geneeskunde. (Promotor(s): van Dongen GAMS, Booij J; copromotor(s): Herscheid JDM)
Al Hussainy R, Verbeek J, van der Born D, Molthoff C, Booij J, Herscheid JKDM, Synthesis, biodistribution and PET studies in rats of F-18-Labeled bridgehead fluoromethyl analogues of WAY-100635. NUCL MED BIOL 2012;39 (7):1068-1076 [PubMed]
Beukers RJ, Contarino MF, Speelman JD, Schuurman PR, Booij J, Tijssen MAJ, Deep Brain Stimulation of the Pallidum is Effective and Might Stabilize Striatal D(2) Receptor Binding in Myoclonus-Dystonia. FRONT NEUROL 2012;3:22 [PubMed]
Booij J, Teune LK, Verberne HJ, The role of molecular imaging in the differential diagnosis of parkinsonism. Q J NUCL MED MOL IM 2012;56 (1):17-26 [PubMed]
Booij J, van Amelsvoort T, Imaging as tool to investigate psychoses and antipsychotics. HANDB EXP PHARMACOL 2012;212 (212):299-337 [PubMed]
Bouet V, Klomp A, Freret T, Wylezinska-Arridge M, Lopez-Tremoleda J, Dauphin F, Boulouard M, Booij J, Gsell W, Reneman L, Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. PSYCHOPHARMACOLOGY 2012;221 (2):329-339 [PubMed]
Braak B, Booij J, Klooker TK, van den Wijngaard RMJ, Boeckxstaens GEE, The dopaminergic system in patients with functional dyspepsia analysed by single photon emission computed tomography (SPECT) and an alpha-methyl-para-tyrosine (AMPT) challenge test. EUR J NUCL MED MOL I 2012;39 (4):642-650 [PubMed]
Crunelle CL. Development of new neurobiological strategies to treat patients with cocaine dependence. s.l.: s.n.; 2012. 167p. ISBN 9789088914171 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Booij J, van den Brink W; copromotor(s): )
Crunelle CL, de Wit TC, de Bruin K, Ramakers RM, van der Have F, Beekman FJ, van den Brink W, Booij J, Varenicline increases in vivo striatal dopamine D-2/3 receptor binding: an ultra-high-resolution pinhole [I-123]IBZM SPECT study in rats. NUCL MED BIOL 2012;39 (5):640-644 [PubMed]
Crunelle CL, Veltman DJ, Booij J, Emmerik-van Oortmerssen K, den Brink W, Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research. BRAIN BEHAV 2012;2 (4):499-523 [PubMed]
Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, Seese A, Koulibaly PM, Akdemir UO, Jonsson C, Koole M, Raith M, Lonsdale MN, George J, Zito F, Tatsch K, Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European I-123-FP-CIT SPECT database. EUR J NUCL MED MOL I 2012;39 (1):188-197 [PubMed]
Djang DSW, Janssen MJR, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, van Berckel BNM, Wanner M, SNM Practice Guideline for Dopamine Transporter Imaging with I-123-Ioflupane SPECT 1.0. J NUCL MED 2012;53 (1):154-163 [PubMed]
Klomp A, den Hollander B, de Bruin K, Booij J, Reneman L, The Effects of Ecstasy (MDMA) on Brain Serotonin Transporters Are Dependent on Age-of-First Exposure in Recreational Users and Animals. PLOS ONE 2012;7 (10):e47524 [PubMed]
Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J, Assessing the Optimal Time Point for the Measurement of Extrastriatal Serotonin Transporter Binding with I-123-FP-CIT SPECT in Healthy, Male Subjects. J NUCL MED 2012;53 (7):1087-1090 [PubMed]
Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, Barber C, Carter J, Walker Z, Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J NEUROL NEUROSUR PS 2012;83 (11):1063-1070 [PubMed]
Reneman L, de Win MML, Booij J, van den Brink W, den Heeten GJ, Freling N, Majoie CBLM, Incidental Head and Neck Findings on MRI in Young Healthy Volunteers: Prevalence and Clinical Implications. AM J NEURORADIOL 2012;33 (10):1971-1974 [PubMed]
Ruhé HG , Booij J, Veltman DJ, Michel MC, Schene AH, Successful Pharmacologic Treatment of Major Depressive Disorder Attenuates Amygdala Activation to Negative Facial Expressions: A Functional Magnetic Resonance Imaging Study. J CLIN PSYCHIAT 2012;73 (4):451-459 [PubMed]
Schouw MLJ, Gevers S, Caan MWA, Majoie CBLM, Booij J, Nederveen AJ, Reneman L, Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI. EUR NEUROPSYCHOPHARM 2012;22 (8):537-545 [PubMed]
van de Giessen E. Neurobiological aspects of obesity: dopamine, srotonin, and imaging. s.l.: s.n.; 2012. 302p. ISBN 9789461821706 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Booij J, van den Brink W; copromotor(s): Baas F, La Fleur SE)
van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J, Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. EUR NEUROPSYCHOPHARM 2012;22 (4):290-299 [PubMed]
van de Giessen E, la Fleur SE, de Bruin K, van den Brink W, Booij J, Free-Choice and No-Choice High-Fat Diets Affect Striatal Dopamine D-2/3 Receptor Availability, Caloric Intake, and Adiposity. OBESITY 2012;20 (8):1738-1740 [PubMed]
van de Giessen E, Nimgaonkar VL, Watson AM, Kodavali C, Baas F, Tanck MWT, de Win MML, van den Brink W, Booij J, Association Tests of Striatal DAT Availability and SNPs That Impact a Novel Splice Variant in the DAT Gene. J NUCL MED 2012;53 (5):839 [PubMed]
Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, Darcourt J, O'Brien J, Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ OPEN 2012;2 (1):e000380 [PubMed]
Al Hussainy R, Verbeek J, van der Born D, Booij J, Herscheid JKDM, Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor. EUR J MED CHEM 2011;46 (12):5728-5735 [PubMed]
Al Hussainy R, Verbeek J, van der Born D, Braker AH, Leysen JE, Knol RJ, Booij J, Herscheid JKDM, Design, Synthesis, Radiolabeling, and in Vitro and in Vivo Evaluation of Bridgehead Iodinated Analogues of N-{2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as Potential SPECT Ligands for the 5-HT(1A) Receptor. J MED CHEM 2011;54 (10):3480-3491 [PubMed]
Auning E, Rongve A, Fladby T, Booij J, Hortobágyi T, Siepel FJ, Ballard C, Aarsland D, Early and presenting symptoms of dementia with lewy bodies. DEMENT GERIATR COGN 2011;32 (3):202-208 [PubMed]
Bloemen OJN. Brain markers of psychosis and autism. s.l.: s.n.; 2011. 191p. ISBN 9789090259338 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Booij J; copromotor(s): van Amelsvoort TAMJ)
Bloemen OJN, Gleich T, de Koning MB, da Silva Alvis F, de Haan L, Linszen DH, Booij J, van Amelsvoort TAMJ, Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. BIOL PSYCHIAT 2011;70 (1):e1-2; author reply e3 [PubMed]
Booij J, Berendse HW, Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. J NEUROL SCI 2011;310 (1-2):40-43 [PubMed]
Booij J, Boot E, van Eeden S, van Amelsvoort T, Unexpected Detection of Nodular Melanoma of the Skin on the Scalp by I-123 IBZM Brain SPECT. CLIN NUCL MED 2011;36 (2):148-149 [PubMed]
Boot E, Booij J, Abeling N, Meijer J, da Silva Alves F, Zinkstok J, Baas F, Linszen D, van Amelsvoort T, Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology. J PSYCHOPHARMACOL 2011;25 (7):888-895 [PubMed]
Boot E, Booij J, Zinkstok JR, Baas F, Swillen A, Owen MJ, Murphy DG, Murphy KC, Linszen DH, van Amelsvoort TA, COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome. SYNAPSE 2011;65 (9):967-970 [PubMed]
Burke SM, van de Giessen E, de Win M, Schilt T, van Herk M, van den Brink W, Booij J, Serotonin and dopamine transporters in relation to neuropsychological functioning, personality traits and mood in young adult healthy subjects. PSYCHOL MED 2011;41 (2):419-429 [PubMed]
Crunelle CL , Schulz S, de Bruin K, Miller ML , van den Brink W, Booij J, Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. EUR NEUROPSYCHOPHARM 2011;21 (2):205-210 [PubMed]
de Weijer BA, van de Giessen E, van Amelsvoort TA, Boot E, Braak B, Janssen IM, van de Laar A, Fliers E, Serlie MJ, Booij J, Lower striatal dopamine D-2/3 receptor availability in obese compared with non-obese subjects. EJNMMI RES 2011;1 (1):37 [PubMed]
Figee M, Booij J, Denys D. Molecular imaging of Obsessive compulsive disorder in: Shenton M E., Turetsky B I., editors. Understandig Neuropsychiatric Disorders: Insights from Neuroimaging. S.l.: Cambridge University Press; 2010., p. -
Knol RJJ, van den Bos JC, Janssen AGM, de Bruin K, van Eck-Smit BLF, Booij J, Synthesis and In Vitro Evaluation of Novel Nortropane Derivatives as Potential Radiotracers for Muscarinic M(2) Receptors. INT J MOL IMAGING 2011;2011:709416 [PubMed]
Ruhé HG, Booij J, Schene AH, Onvoldoende response op een standaarddosering van een SSRI bij unipoliare depressie: dosisverhoging?. PSYFAR 2011;6 (1):19-23
Ruhé HG, Booij J, Schene AH, Wat te doen als de eerste pil niet werkt: dosisverhoging of toch liever switchen?. PSYFAR 2011;6 (1):24-27
van de Giessen E, Groot PFC, Booij J, van den Brink W, Veltman DJ, Nederveen AJ, Functional MR imaging on an open 1T MR imaging system: exploiting the advantages of an open MR imaging system for functional MR imaging. AM J NEURORADIOL 2011;32 (5):903-907 [PubMed]
Zoons E, Booij J, Nederveen AJ, Dijk JM, Tijssen MAJ, Structural, functional and molecular imaging of the brain in primary focal dystonia-A review. NEUROIMAGE 2011;56 (3):1011-1020 [PubMed]
Booij J, Arkies H, Primaire progressieve afasie. TIJDSCHR NUCL GENEESKD 2010;32 (2):514-515
Booij J, van Amelsvoort T, Boot E, Co-Occurrence of Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome: Potential Role for Dopamine Transporter Imaging. AM J MED GENET A 2010;152A (11):2937-2938 [PubMed]
Boot E, Booij J, Zinkstok JR, de Haan L, Linszen DH, Baas F, van Amelsvoort TA, Striatal D₂ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study. J PSYCHOPHARMACOL 2010;24 (10):1525-1531 [PubMed]
Boot EHJG. 22q11 Deletion syndrome and neurotransmitter systems in unchallenged and chalenged conditions. s.l.: s.n.; 2010. 175p. ISBN 9789090254487 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Booij J; copromotor(s): van Amelsvoort TAMJ)
Crunelle CL, Miller ML, Booij J, van den Brink W, The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review. EUR NEUROPSYCHOPHARM 2010;20 (2):69-79 [PubMed]
Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Någren K, Nobili F, Walker Z, van Laere K, EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. EUR J NUCL MED MOL I 2010;37 (2):443-450 [PubMed]
Minnee RC, Bemelman WA, Donselaar-van der Pant KAMI, Booij J, ter Meulen S, ten Berge IJM, Legemate DA, Bemelman FJ, Idu MM, Risk Factors for Delayed Graft Function After Hand-Assisted Laparoscopic Donor Nephrectomy. TRANSPL P 2010;42 (7):2422-2426 [PubMed]
Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW, Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J NEUROL NEUROSUR PS 2010;81 (4):396-399 [PubMed]
Rube HG, Booij J, van Weert HC, Reitsma JB, Franssen EJ, Michel MC, Schene AH, Antwoord aan Moleman. TIJDSCHR PSYCHIATR 2010;52 (11):802-804
Ruhé HG, Booij J, van Weert HC, Reitsma JB, Franssen EJ, Michel MC, Schene A, Dosisverhoging van SSRI'S bij depressie; niet aan te bevelen in richtlijnen. TIJDSCHR PSYCHIATR 2010;52 (9):615-625 [PubMed]
van de Giessen E, Booij J, The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men. EUR J NUCL MED MOL I 2010;37 (8):1507-1511 [PubMed]
van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F, Kapucu OL, Walker Z, Någren K, Tatsch K, Darcourt J, EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. EUR J NUCL MED MOL I 2010;37 (2):434-442 [PubMed]
Veltman DJ, Ruhé HG, Booij J, Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings. CURR PHARM DESIGN 2010;16 (18):1979-1989 [PubMed]
Beekman FJ, Vastenhouw B, van der Wilt G, Vervloet M, Visscher R, Booij J, Gerrits M, Ji C, Ramakers R, van der Have F, 3-D Rat Brain Phantom for High-Resolution Molecular Imaging. P IEEE 2009;97 (12):1997-2005
Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TAMJ, Tijssen MAJ, Reduced striatal D-2 receptor binding in myoclonus-dystonia. EUR J NUCL MED MOL I 2009;36 (2):269-274 [PubMed]
Crunelle CL, Miller ML, de Bruin K, van den Brink W, Booij J, Varenicline increases striatal dopamine D(2/3) receptor binding in rats. ADDICT BIOL 2009;14 (4):500-502 [PubMed]
Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S, Amyloid PET and MRI in Alzheimer's Disease and Mild Cognitive Impairment. CURR ALZHEIMER RES 2009;6 (3):312-319 [PubMed]
Ilse Nijs I, Ingmar Franken I, Booij J. Verslavingsmechanismen bij excessief eetgedrag en obesitas in: Franken IHA, van den Brink W, editors. Handboek verslaving. Utrecht: De Tijdstroom; 2009. hdst 25, p. 14-538
Kapucu OL, Nobili F, Varrone A, Booij J, Vander Borght T, Någren K, Darcourt J, Tatsch K, van Laere KJ, EANM procedure guideline for brain perfusion SPECT using (99m)Tc-labelled radiopharmaceuticals, version 2. EUR J NUCL MED MOL I 2009;36 (12):2093-2102 [PubMed]
Knol RJJ, de Bruin K, van Eck-Smit BLF, Pimlott S, Wyper DJ, Booij J, In vivo [(123)I]CNS-1261 binding to D-serine-activated and MK801-blocked NMDA receptors: A storage phosphor imaging study in rats. SYNAPSE 2009;63 (7):557-564 [PubMed]
Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HTS, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG, Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. MOVEMENT DISORD 2009;24 (4):500-508 [PubMed]
O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, Marquardt M, Reininger C, Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. BRIT J PSYCHIAT 2009;194 (1):34-39 [PubMed]
Ruhé E, Booij J, van Weert H, Reitsma J, Fransen E, Michel M, Schene A, Dosisverhoging SSRI's bij depressie is niet zinvol. HUISARTS WET 2009;6 (52):289-296
Ruhé HG , Booij J, Reitsma JB, Schene AH, Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. EUR J NUCL MED MOL I 2009;36 (5):841-849 [PubMed]
Ruhé HG , Booij J, Weert HCV, Reitsma JB, Fransen EJF, Michel MC, Schene AH, Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. NEUROPSYCHOPHARMACOL 2009;34 (4):999-1010 [PubMed]
Ruhé HG , Ooteman W, Booij J, Michel MC, Moeton M, Baas F, Schene AH, Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. PHARMACOGENET GENOM 2009;19 (1):67-76 [PubMed]
van de Giessen EM, de Win MML, Tanck MWT, van den Brink W, Baas F, Booij J, Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3. J NUCL MED 2009;50 (1):45-52 [PubMed]
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, van Laere K, EANM procedure guidelines for PET brain imaging using [(18)F]FDG, version 2. EUR J NUCL MED MOL I 2009;36 (12):2103-2110 [PubMed]
Zijlstra F, Veltman DJ, Booij J, van den Brink W, Franken IHA, Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. DRUG ALCOHOL DEPEN 2009;99 (1-3):183-192 [PubMed]
Bennink RJ, Booij J, Positieve octreoidescintigrafie bij nasopharyngeal carcinoom. TIJDSCHR NUCL GENEESKD 2008;29 (3):49-49
Bennink RJ, van der Meulen FW, Freling NJ, Booij J, Somatostatin receptor scintigraphy in nasopharyngeal carcinoma. CLIN NUCL MED 2008;33 (8):558-561 [PubMed]
Booij J, Kemp P, Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. EUR J NUCL MED MOL I 2008;35 (2):424-438 [PubMed]
Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA, AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. EUR J NUCL MED MOL I 2008;35 (7):1350-1356 [PubMed]
Boot E, Booij J, Zinkstok J, Abeling N, de Haan L, Baas F, Linszen D, van Amelsvoort T, Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. NEUROPSYCHOPHARMACOL 2008;33 (6):1252-1258 [PubMed]
Caretti V, Stoffers D, Winogrodzka A, Isaias IU, Costantino G, Pezzoli G, Ferrarese C, Antonini A, Wolters EC, Booij J, Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [I-123]beta-CIT SPECT study. J NEURAL TRANSM 2008;115 (5):721-729 [PubMed]
de Win MML, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W, Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. BRAIN 2008;131 (Part 11):2936-2945 [PubMed]
de Win MML, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, Ramsey NF, den Heeten GJ, van den Brink W, Neurotoxic effects of ecstasy on the thalamus. BRIT J PSYCHIAT 2008;193 (4):289-296 [PubMed]
Jongen C, de Bruin K, Beekman F, Booij J, SPECT imaging of D-2 dopamine receptors and endogenous dopamine release in mice. EUR J NUCL MED MOL I 2008;35 (9):1692-1698 [PubMed]
Knol RJJ. Fundamental studies on radiotracers intended for receptor imaging in dementia. s.l.: s.n.; 2008. 244p. ISBN 9789090236148 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Eck-Smit BLF; copromotor(s): Booij J)
Knol RJJ, de Bruin K, de Jong J, van Eck-Smit BLF, Booij J, In vitro and ex vivo storage phosphor imaging of short-living radioisotopes. J NEUROSCI METH 2008;168 (2):341-357 [PubMed]
Knol RJJ, de Bruin K, van Eck-Smit BLF, Booij J, No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats. EUR J NUCL MED MOL I 2008;35 (3):598-604 [PubMed]
Lindauer RJL, Booij J, Habraken JBA, van Meijel EPM, Uylings HBM, Olff M, Carlier IVE, den Heeten GJ, van Eck-Smit BLF, Gersons BPR, Effects of psychotherapy on regional cerebral blood flow during trauma imagery in patients with post-traumatic stress disorder: a randomized clinical trial. PSYCHOL MED 2008;38 (4):543-554 [PubMed]
Ruhé HG. Dose-escalation in the picture. Pharmacological and imaging studies in depression. s.l.: s.n.; 2008. 300p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schene AH; copromotor(s): Booij J)
Visser I , Lavini C, Booij J, Reneman L, Majoie C, de Boer AGEM, Wekking EM, de Joode EA, Van der Laan G , van Dijk FJH, Schene AH, den Heeten GJ, Cerebral impairment in chronic solvent-induced encephalopathy. ANN NEUROL 2008;63 (5):572-580 [PubMed]
Zijlstra F, Booij J, van den Brink W, Franken IHA, Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. EUR NEUROPSYCHOPHARM 2008;18 (4):262-270 [PubMed]
Berendse HW, Booij J, Leenders KL. Neuroimaging in movement disorders: PET and SPECT [ch.32] in: Wolters EC, van Laar T, Berendse HW, editors. Parkinsonism and related disorders. Amsterdam: VU University Press; 2007., p. 505-521
Booij J, Berendse HW, Onderscheid tussen medicatie-geinduceerd parkinsonisme en de ziekte van parkinson. TIJDSCHR NEUROPSYCHIATR GEDRAGSPSYCHIATR 2007;6:45-47
Booij J, Claus JJ, DAT-imaging differentieert tussen dementie met Lewy-lichaampjes en de ziekte van Alzheimer. TIJDSCHR NEUROPSYCHIATR GEDRAGSPSYCHIATR 2007;6:144-146
Booij J, de Jong J, de Bruin K, Knol R, de Win MML, van Eck-Smit BLF, Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy control subjects. J NUCL MED 2007;48 (3):359-366 [PubMed]
Booij J, Knol RJJ, SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. PARKINSONISM RELAT D 2007;13 (Suppl. 3):S425-S428 [PubMed]
de Win MML. Neurotoxity of ecstacy: causality, course, and clinical relevance. s.l.: s.n.; 2007. 335p. ISBN 9789090214924 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van den Brink W, den Heeten GJ; copromotor(s): Booij J, Reneman L)
de Win MML, Reneman L, Jager G, Vlieger EJP, Olabarriaga SD, Lavini C, Bisschops I, Majoie CBLM, Booij J, den Heeten GJ, van den Brink W, A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. NEUROPSYCHOPHARMACOL 2007;32 (2):458-470 [PubMed]
Haaxma CA, Bloem BR, Borm GF, Oyen WJG, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MWIM, Gender differences in Parkinson's disease. J NEUROL NEUROSUR PS 2007;78 (8):819-824 [PubMed]
McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C, Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. LANCET NEUROL 2007;6 (4):305-313 [PubMed]
Vastenhouw B, van der Have F, van der Linden AJA, von Oerthel L, Booij J, Burbach JPH, Smidt MP, Beekman FJ, Movies of dopamine transporter occupancy with ultra-high resolution focusing pinhole SPECT. MOL PSYCHIATR 2007;12 (11):984-987 [PubMed]
Abeling NG, Duran M, Bakker HD, Stroomer L, Thöny B, Blau N, Booij J, Poll-The BT, Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. MOL GENET METAB 2006;89 (1-2):116-120 [PubMed]
Booij J, de Bruin K, Gunning WB, Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study. NUCL MED BIOL 2006;33 (3):409-411 [PubMed]
Booij J, de Win MML, Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. NUCL MED BIOL 2006;33 (2):185-191 [PubMed]
de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D, Occupancy of dopamine D-2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. PSYCHOPHARMACOLOGY 2006;183 (4):500-505 [PubMed]
de Win MML, Schilt T, Reneman L, Vervaeke H, Jager G, Dijkink S, Booij J, van den Brink W, Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J PSYCHOPHARMACOL 2006;20 (2):226-235 [PubMed]
Reneman L, de Win MML, van den Brink W, Booij J, den Heeten GJ, Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J PSYCHOPHARMACOL 2006;20 (2):164-175 [PubMed]
Reneman L, Schilt T, de Win MM, Booij J, Schmand B, van den Brink W, Bakker O, Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J PSYCHOPHARMACOL 2006;20 (3):389-399 [PubMed]
Verberne HJ, de Bruin K, Habraken JBA, Somsen GA, Eersels JLH, Moet F, Booij J, van Eck-Smit BLF, No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity. EUR J NUCL MED MOL I 2006;33 (4):483-490 [PubMed]
Andringa G, Drukarch B, Bol JGJM, de Bruin K, Sorman K, Habraken JBA, Booij J, Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. NEUROIMAGE 2005;26 (4):1150-1158 [PubMed]
de Haan L, Booij J, Lavalye J, van Amelsvoort T, Linszen D, Subjective experiences during dopamine depletion. AM J PSYCHIAT 2005;162 (9):1755 [PubMed]
de Haan L, Lavalaye J, Booij J, Linszen D, Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. AM J PSYCHIAT 2005;162 (8):1544-1545 [PubMed]
de Win MML, Habraken JBA, Reneman L, van den Brink W, den Heeten GJ, Booij J, Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. NEUROPSYCHOPHARMACOL 2005;30 (5):996-1005 [PubMed]
de Win MML, Jager G, Vervaeke HKE, Schilt T, Reneman L, Booij J, Verhulst FC, den Heeten GJ, Ramsey NF, Korf DJ, van den Brink W, The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. INT J METH PSYCH RES 2005;14 (4):167-185 [PubMed]
Franken IHA, Booij J, van den Brink W, The role of dopamine in human addiction: From reward to motivated attention. EUR J PHARMACOL 2005;526 (1-3):199-206 [PubMed]
Franken IHA, Zijlstra C, Booij J, van den Brink W. Imaging the addicted brain: reward, craving, and cognitive processes in: Wiers RW, Stacy AW, editors. Handbook of Implicit cognition and addiction. London: SAGE Publications; 2005., p. 185-199
Janssen AG, Habraken JBA, Booij J, DaTSCAN SPECT (afbeelden van het striatum): achtergonden en praktische aspecten. TIJDSCHR NUCL GENEESKD 2005;27 (3):103-111
Krygowska-Wajs A, Kachergus JM, Hulihan MM, Farrer MJ, Searcy JA, Booij J, Berendse HW, Wolters EC, Wszolek ZK, Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. J NEURAL TRANSM 2005;112 (11):1487-1502 [PubMed]
Lindauer RJL. Effects of psychotherapy on the biology posttraumatic stress disorder: brain imaging and neurophysiological correlates. S.l.: s.n.; 2005. 208p. ISBN 90-64642-23-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Gersons BPR, den Heeten GJ; copromotor(s): Booij J, Carlier IVE, Olff M)
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW, Olfaction and early detection of Parkinson's disease - Reply. ANN NEUROL 2005;57 (1):157-158
Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW, Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. EUR J NUCL MED MOL I 2005;32 (6):689-695 [PubMed]
Winogrodzka A, Booij J, Wolters EC, Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. PARKINSONISM RELAT D 2005;11 (8):475-484 [PubMed]
Winogrodzka A, Wagenaar RC, Booij J, Wolters EC, Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. ARCH PHYS MED REHAB 2005;86 (2):183-189 [PubMed]
Booij J, Guest editorial Neuroimaging. TIJDSCHR NUCL GENEESKD 2004;26 (3):79-81
Booij J, van Eck-Smit BLF. Dopaminetransporter- en dopamine-D2-receptorscintigrafie met SPECT bij de ziekte van Parkinson in: Hovestadt A, editor. Ziekte van Parkinson. Capita Selecta. S.l.: s.n.; 2004., p. 1-7
de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D, Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. CAN J PSYCHIAT 2004;49 (5):290-296 [PubMed]
de Win MML, de Jeu RAM, de Bruin K, Habraken JBA, Reneman L, Booij J, den Heeten GJ, Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. EUR NEUROPSYCHOPHARM 2004;14 (3):185-189 [PubMed]
de Win MML, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W, Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. PSYCHOPHARMACOLOGY 2004;173 (3-4):376-382 [PubMed]
Knol RJJ, Doornbos T, van den Bos JC, de Bruin K, Pfaffendorf M, Aanhaanen W, Janssen AGM, Vekemans JAJM, van Eck-Smit BLF, Booij J, Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M-2 receptors with SPET. NUCL MED BIOL 2004;31 (1):111-123 [PubMed]
Lindauer RJL, Booij J, Habraken JBA, Uylings HBM, Olff M, Carlier IVE, den Heeten GJ, van Eck-Smit BLF, Gersons BPR, Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder. BIOL PSYCHIAT 2004;56 (11):853-861 [PubMed]
Loonen AJM, Knol RJJ, Booij J, Frontotemporale dementie. TIJDSCHR NUCL GENEESKD 2004;26 (3):89-92
Mirzaei S, Gelpi E, Booij J, Rodrigues M, Neumann I, Zaknun J, Koehn H, Knoll P, New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. CURR ALZHEIMER RES 2004;1 (3):219-229 [PubMed]
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW, Idiopathic hyposmia as a preclinical sign of Parkinson's disease. ANN NEUROL 2004;56 (2):173-181 [PubMed]
Booij J, de Bruin K, de Win MML, Lavini C, den Heeten GJ, Habraken JBA, Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. NUCL MED BIOL 2003;30 (6):643-649 [PubMed]
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PMAJ, Linszen D, Subjective experience and D-2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized, double-blind study. AM J PSYCHIAT 2003;160 (2):303-309 [PubMed]
Reneman L, Booij J, den Heeten GJ, van den Brink W. Beeldvormend onderzoek naar de mogelijke neurotoxiciteit van ecstasy (MDMA) (Hfdst 6) in: Schene AH, de Boer F, Heeren TJ, Henselmans HWJ, Sabbe B, van Weeghel J, editors. Jaarboek voor psychiatrie en psychotherapie 2003-2004. Houten/Mechelen: Bohn Stafleu Van Loghum; 2003., p. 86-102
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC, [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J NEUROL NEUROSUR PS 2003;74 (3):294-298 [PubMed]
Winogrodzka A, Booij J, Wolters ECH, The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease - Reply (letter). J NEUROL NEUROSUR PS 2003;74 (10):1447
Berendse HW, Booij J, Stoffers D, Ponsen MM, Hijman R, Wolters EC, Presymptomatische detectie van de ziekte van Parkinson. TIJDSCHR GERONTOL GERIATR 2002;33 (2):70-77 [PubMed]
Booij J, de Bruin K, Habraken JBA, Voorn P, Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. EUR J NUCL MED MOL I 2002;29 (9):1221-1224 [PubMed]
Reneman L, Booij J, den Heeten GJ. Beeldvormend onderzoek naar de mogelijke neurotoxiciteit van ecstacy (MDMA) in: Handboek verslaving. S.l.: s.n.; 2002.
Reneman L, Booij J, den Heeten GJ, van den Brink W, Effects of MDMA (ecstasy) use and abstention on serotonin neurons - Reply. LANCET 2002;359 (9317):1617-1618
Reneman L, Booij J, Habraken JBA, de Bruin K, Hatzidimitriou G, den Heeten GJ, Ricaurte GA, Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. SYNAPSE 2002;46 (3):199-205 [PubMed]
Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B, den Heeten GJ, van den Brink W, Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study--preliminary report. PSYCHOPHARMACOLOGY 2002;159 (3):335-340 [PubMed]
Reneman L, Booij J, Schmand BA, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W, Korte- en langetermijneffecten van ecstacy op serotonineproducerende hersencellen en het geheugen. NED TIJDSCHR GENEESKD 2002;146 (47):2240-2246
Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff FA, Booij J, The acute and chronic effects of MDMA ("Ecstasy") on cortical 5-HT2A receptors in rat and human brain. NEUROPSYCHOPHARMACOL 2002;26 (3):387-396 [PubMed]
Zijlmans J, Booij J, Valk J, Lees A, Horstink M, Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway. MOVEMENT DISORD 2002;17 (5):1086-1087 [PubMed]
Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC, Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. ANN NEUROL 2001;50 (1):34-41 [PubMed]
Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC, Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. SYNAPSE 2001;39 (2):101-108 [PubMed]
Booij J, Speelman JD, Horstink MW, Wolters EC, The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. EUR J NUCL MED 2001;28 (3):266-272 [PubMed]
Habraken JB, de Bruin K, Shehata M, Booij J, Bennink R, van Eck Smit BL, Busemann Sokole E, Evaluation of high-resolution pinhole SPECT using a small rotating animal. J NUCL MED 2001;42 (12):1863-1869 [PubMed]
Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA, Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. PSYCHOPHARMACOLOGY 2001;156 (1):53-57 [PubMed]
Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA, Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. SCHIZOPHR RES 2001;47 (1):59-67 [PubMed]
Lavalaye J, Sarlet A, Booij J, Linszen DH, Reneman L, Gersons BP, van Royen EA, Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. PSYCHOPHARMACOLOGY 2001;155 (1):107-109 [PubMed]
Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W, Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. LANCET 2001;358 (9296):1864-1869 [PubMed]
Reneman L, Booij J, Majoie CBLM, van den Brink W, den Heeten GJ, Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. HUM PSYCHOPHARM CLIN 2001;16 (8):579-588 [PubMed]
Reneman L, de Bruin K, Lavalaye J, Gunning WB, Booij J, Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus. SYNAPSE 2001;39 (3):193-200 [PubMed]
Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J, Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. ARCH GEN PSYCHIAT 2001;58 (10):901-906 [PubMed]
van de Warrenburg BP, Lammens M, Lücking CB, Denèfle P, Wesseling P, Booij J, Praamstra P, Quinn N, Brice A, Horstink MW, Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. NEUROLOGY 2001;56 (4):555-557 [PubMed]
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC, [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J NEURAL TRANSM 2001;108 (8-9):1011-1019 [PubMed]
Winogrodzka A, Wagenaar RC, Bergmans P, Vellinga A, Booij J, van Royen EA, van Emmerik RE, Stoof JC, Wolters EC, Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients. MOVEMENT DISORD 2001;16 (6):1033-1040 [PubMed]
de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J, Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. AM J PSYCHIAT 2000;157 (6):1019-1020 [PubMed]
Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA, Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. EUR J NUCL MED 2000;27 (7):867-869 [PubMed]
Lavalaye J, Knol RJ, de Bruin K, Reneman L, Janssen AG, Booij J, [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. EUR J NUCL MED 2000;27 (3):346-349 [PubMed]
Reneman L, Booij J, Schmand B, van den Brink W, Gunning B, Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. PSYCHOPHARMACOLOGY 2000;148 (3):322-324 [PubMed]
Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ, MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AM J NEURORADIOL 2000;21 (6):1001-1007 [PubMed]
Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA, One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J NUCL MED 1999;40 (5):753-761 [PubMed]
Booij J, Tissingh G, Winogrodzka A, van Royen EA, Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. EUR J NUCL MED 1999;26 (2):171-182 [PubMed]
Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA, Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J NUCL MED 1999;40 (7):1091-1097 [PubMed]
Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA, Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. PSYCHIAT RES 1999;92 (1):33-44 [PubMed]
Reneman L, Booij J, Lavalaye J, de Bruin K, de Wolff FA, Koopmans RP, Stoof JC, den Heeten GJ, Comparative in vivo study of iodine-123-labeled beta-CIT and nor-beta-CIT binding to serotonin transporters in rat brain. SYNAPSE 1999;34 (1):77-80 [PubMed]
Stoof JC, Winogrodzka A, van Muiswinkel FL, Wolters EC, Voorn P, Groenewegen HJ, Booij J, Drukarch B, Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. EUR J PHARMACOL 1999;375 (1-3):75-86 [PubMed]
Booij J, Busemann Sokole E , Stabin MG, Janssen AG, de Bruin K, van Royen EA, Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. EUR J NUCL MED 1998;25 (1):24-30 [PubMed]
Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA, Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J NUCL MED 1998;39 (11):1879-1884 [PubMed]
Booij J, Knol RJ, Reneman L, de Bruin K, Janssen AG, van Royen EA, Iodine-123 labelled nor-beta-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. EUR J NUCL MED 1998;25 (12):1666-1669 [PubMed]
Hulshof MC, Rehmann CJ, Booij J, van Royen EA, Bosch DA, González González D, Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. RADIOTHER ONCOL 1998;48 (2):135-142 [PubMed]
Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC, Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J NEUROL 1998;245 (1):14-20 [PubMed]
Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC, Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J NUCL MED 1998;39 (7):1143-1148 [PubMed]
Booij J, Andringa G, Rijks LJ, Vermeulen RJ, de Bruin K, Boer GJ, Janssen AG, van Royen EA, [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. SYNAPSE 1997;27 (3):183-190 [PubMed]
Booij J, Korn P, Linszen DH, van Royen EA, Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. EUR J NUCL MED 1997;24 (6):674-677 [PubMed]
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA, [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J NEUROL NEUROSUR PS 1997;62 (2):133-140 [PubMed]
Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, van Royen EA, Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. EUR J NUCL MED 1997;24 (1):68-71 [PubMed]
Claus JJ, Dubois EA, Booij J, Habraken J, de Munck JC, van Herk M, Verbeeten B Jr, van Royen EA, Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. EUR J NUCL MED 1997;24 (6):602-608 [PubMed]
Horstink CA, Praamstra P, Horstink MW, Berger HJ, Booij J, van Royen EA, Low striatal D2 receptor binding as assessed by [123I]IBZM SPECT in patients with writer's cramp. J NEUROL NEUROSUR PS 1997;62 (6):672-673 [PubMed]
Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, van Royen EA, [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. EUR J NUCL MED 1997;24 (9):1171-1174 [PubMed]
Tissingh G, Bergmans P, Winogrodzka A, Stoof JC, Wolters EC, Booij J, van Royen EA, Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J NUCL MED 1997;38 (8):1271-1272 [PubMed]
Rijks LJ, Booij J, Doornbos T, Boer GJ, Ronken E, de Bruin K, Vermeulen RJ, Janssen AG, van Royen EA, In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligands. SYNAPSE 1996;23 (3):201-207 [PubMed]
Vermeulen RJ, Wolters EC, Tissingh G, Booij J, Janssen AG, Habraken J, Sokole-Busemann E, Stoof JC, van Royen EA, Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease. NUCL MED BIOL 1995;22 (8):985-991 [PubMed]
Key publications

Joling M, Vriend C, van den Heuvel OA, Raijmakers PGHM, Jones PA, Berendse HW, Booij J, Analysis of Extrastriatal (123)I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. J NUCL MED 2017;58 (7):1117-1123 [PubMed]
Bakker G, Vingerhoets WA, van Wieringen JP, de Bruin K, Eersels J, de Jong J, Chahid Y, Rutten BP, Dubois S, Watson M, Mogg AJ, Xiao H, Crabtree M, Collier DA, Felder CC, Barth VN, Broad LM, Bloemen OJ, van Amelsvoort TA, Booij J, I-123-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M-1 In Vivo. J NUCL MED 2015;56 (2):317-322 [PubMed]
Crunelle CL, van den Brink W, Dom G, Booij J, Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. BRIT J PSYCHIAT 2014;204 (6):486-487 [PubMed]
Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH, Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. ACTA NEUROPATHOL 2017;133 (4):535-545 [PubMed]
Gevonden M, Booij J, van den Brink W, Heijtel D, van Os J, Selten JP, Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia. JAMA PSYCHIAT 2014;71 (12):1364-1372 [PubMed]


All Publications

Research programmes

Neuroreceptor imaging in addiction and neuropsychiatric disorders

  • The role of dopamine in PKU
  • Imaging of dopamine transporters to differentiate dementia with Lewy bodies from Alzheimer’s disease
  • Serotonin transporter imaging in depression, and the occupancy of the serotonin transporter by the SSRI paroxetine
  • Assessment of loss of serotonin transporters in Ecstasy users
  • Detection of loss of dopamine D2 receptor binding in heroin and cocaine users
  • Effects of methylphenidaat in ADHD patients with comorbid cocaine addiction
  • Effects of varenicline on dopamine D2 receptors and craving
  • Imaging of the occupancy of D2 receptors by endogenous dopamine (acute dopamine depletion paradigm) in healthy controls and VCFS patients
  • The role of the dopaminergic and serotonergic system in focal dystonia
  • Dopamine D2 receptors and its role in obesity

Theme: Neurological and Psychiatric Disorders

Faculty
Prof. dr. J. Booij

Postdocs
Dr. S.M. Adriaanse
Dr. J.L.H. Eersels

PhD Students
M.C. Gumbs MSc
Drs. S.R. Suwijn
Drs. E. Zoons
Drs. I.M.C. Bakker (Maastricht University)
E.D.A. van Duin (Maastricht University)
Drs. M. Gevonden MSc (Maastricht University & Rivierduinen)
Drs. M. Joling (VUMC)
Drs. R. Schalbroeck (LUMC)
Drs. W.A.M. Vingerhoets (Maastricht University)

Other research related activities
  • Membership of advisory board / Consultant, GE
  • Membership of advisory board / Consultant, Bayer Schering Pharma
Current research funding
  • AMC
  • GE Healthcare Limited
  • ZonMw (Vrijgesteld)